Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

2.8 -1.75

Buy Sell

Overview

Share price change

24h

Current

Min

2.79

Max

2.89

Key metrics
By Trading Economics
Income	1.2M -31M
Sales	-70K 1.3M
EPS	-0.26
Profit margin	-2,402.848
Employees	161
EBITDA	14M -28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+79.14% upside

Dividends
By Acuity
Next Earnings	10 sie 2026

Market Stats
By TradingEconomics
Market Cap	108M 361M
Previous open	4.55
Previous close	2.8

News Sentiment

By Acuity

50%

145 / 340 Ranking in Healthcare

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 lip 2026, 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

79.14% upside

12 Months Forecast

Average 4.98 USD 79.14%

High 8 USD

Low 2.2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

145 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.